Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

5 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.

Probiotics offer little in terms of GI symptoms in systemic sclerosis

06 Jun 2019

Treatment with probiotics falls short of improving gastrointestinal (GI) symptoms in patients with systemic sclerosis (SSc), a study has shown.

The study randomized 73 SSc patients with a moderate–severe total score on the University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (UCLA GIT 2.0) instrument to receive a daily dose of probiotics (Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus and Bifidobacterium lactis, 109 colony-forming units per capsule; n=37) or placebo (n=36) for 8 weeks.

After 8 weeks of treatment, the primary outcome of change in UCLA GIT 2.0 total score did not significantly differ between the two treatment groups.

However, probiotics treatment produced a significant decrease in the proportion of Th17 cells compared with placebo (p=0.003). There was no between-group difference observed in the proportion of Th1, Th2 and regulatory T cells or in the Health Assessment Questionnaire-Disability Index (HAQ-DI) score.

Although probiotics did not improve GI symptoms in SSc patients, the improvement in Th17 cell levels suggests that the treatment exerts an immunomodulatory effect on SSc, researchers pointed out.

SSc is a multisystem connective tissue disorder of unknown aetiology, and the GI tract is affected in the vast majority (90 percent) of patients. Gut involvement—with symptoms ranging from gastro-oesophageal reflux to faecal incontinence—is the leading cause of morbidity and the third most common cause of mortality in patients with SSc. [Rheumatology 2019;49:1770-1775]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

5 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.